Pfizer seeks FDA clearance for Sutent in rare pancreatic malignancy
Final results from the randomized trial of Sutent in pancreatic neuroendocrine tumors was released in Orlando today, and they are good enough to send Pfizer to the FDA seeking an approval. Evidently Sutent extended overall (a secondary endpoint) and progression-free survival in the studies, according to researchers.
This was in a pretreated population of patients. Sutent was compared to placebo, so the setting appears to be people with advanced disease.
Sutent is already approved in kidney cancer and certain forms of sarcoma, though it costs more per month than a mortgage payment.
This will be good news for Steve Jobs, who has pancreatic neuroendocrine cancer (and can probably afford these super-expensive pills). My experience with it is similar to his--long intervals of quiet disease punctuated by growth and progression. It will be good to have another weapon in our armamentarium.
- 7990 reads
